$Arcturus Therapeutics Ltd.(ARCT)$Arcturus believes cellular responses induced by its ** vaccine candidate will compensate for the underwhelming neutralizing antibody levels in its interim Phase I/II data.Eng Eong Ooi, a member of Arcturus’ vaccine platform SAB, hypothesized the robust T cell responses were behind the low antibody production following the second 5 µg ARCT-021 administration.Ooi said their data showed that antibodies were not necessary for protection against SARS-CoV-2.
$The9(NCTY)$ For others who want a new bitcoin play.... check out $IPOE ... it just announced merger with fintech SoFi which also provides buying of bitcoins and crypto using its app.
$GameStop(GME)$Finally some official news from GameStop! $GME appoints Matt Francis as Chief Technology Officer. He was previously engineering leader at Amazon's AWS. Could be a big news for GameStop as it revamps its e-commerce biz.
$Ehang Holdings Ltd(EH)$ EHang Wins Urban Air Mobility Call from Paris Region! Wow! This is great news! Such a pity today looks like most stocks are in the red.
$Arcturus Therapeutics Ltd.(ARCT)$Lots of negativity surrounding the Arcturus Covid-19 vaccine data. The low neutralizing titers (antibodies) may look disappointing but the response of CD4 and CD8 T cells are very good and could prevent Covid-19 infection. Immunity is more than just antibodies.T-cells response data for the following vaccines. Biontech/Pfizer: 0.4%, Moderna: 0.2%. Arcturus is a whopping 4 to 8%! You get lesser antibodies with Arcturus but more T-Cells. Antibody immunity is seasonal. T-Cell immunity lasts much longer.